MedImmune, Astra Zeneca’s Biologics Arm, Acquires AlphaCore Pharma
April 3rd, 2013
Press Release April 3 2013
In the News
NIH BrIDGs Program to Support Development of ACP-501 for Treatment of Familial LCAT Deficiency
December 10th, 2012
see link for details http://www.nih.gov/news/health/dec2012/ncats-04.htm
AlphaCore Granted Orphan Drug Designation for ACP-501 (rhLCAT) by European Medicines Agency
November 2nd, 2012
ACP-501 EU Orphan Designation Press Release November 2 2012 (Please click link above to view Press Release PDF)
AlphaCore Reports Positive Phase 1 Results for ACP-501 (rhLCAT) in Patients with Stable Atherosclerosis
October 9th, 2012
ACP-501 Phase 1 Results Press Release October 9 2012 (Please click on Link to View Press Reslease)
AlphaCore Pharma Initiates ACP-501 (rhLCAT) Clinical Trial in Patients with Coronary Heart Disease
March 30th, 2012
(Please click on Link to View Press Reslease) ACP-501 (rhLCAT) Phase 1 initiation press release March 30 2012
